Value of PD-L1, PD-1, and CTLA-4 Expression in the Clinical Practice as Predictors of Response to Nivolumab and Ipilimumab in Monotherapy in Patients With Advanced Stage Melanoma-Reference-Cited by-同舟云学术

Value of PD-L1, PD-1, and CTLA-4 Expression in the Clinical Practice as Predictors of Response to Nivolumab and Ipilimumab in Monotherapy in Patients With Advanced Stage Melanoma

Published:2020-12-29 Issue:6 Volume:43 Page:423-428
ISSN:0193-1091
Container-title:The American Journal of Dermatopathology
language:en
Short-container-title:

Author:

Santos-Briz Angel,Cañueto Javier,Carmen Sofía del,Barrios Beatriz,Yuste Manuela,Bellido Lorena,Ludeña María Dolores,Román Concepción

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Dermatology,General Medicine,Pathology and Forensic Medicine

Reference28 articles.

1. 5‐year survival outcomes in patients (pts) with advanced melanoma treated with pembrolizumab (pembro) in KEYNOTE‐001;Hamid;J Clin Oncol.,2018

2. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma;Robert;N Engl J Med.,2011

3. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-com-parison cohort of a phase 1 trial;Robert;Lancet.,2014

4. Nivolumab in previously untreated melanoma without BRAF mutation;Robert;N Engl J Med.,2015

5. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial;Weber;Lancet Oncol.,2015

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PD-L1 expression as a potential predictor of immune checkpoint inhibitor efficacy and survival in patients with recurrent or metastatic nasopharyngeal cancer: a systematic review and meta-analysis of prospective trials;Frontiers in Oncology;2024-06-03

2. Emerging prognostic biomarkers in advanced cutaneous melanoma: a literature update;Expert Review of Molecular Diagnostics;2024-02

3. Detailed characterization of PD-1/PD-L1 and CTLA4 expression and tumor-infiltrating lymphocytes in yolk sac tumors;Human Immunology;2023-10

4. Comprehensive analyses of A 12-metabolism-associated gene signature and its connection with tumor metastases in clear cell renal cell carcinoma;BMC Cancer;2023-03-23

5. Identification and Validation of Ferroptosis-Related DNA Methylation Signature for Predicting the Prognosis and Guiding the Treatment in Cutaneous Melanoma;International Journal of Molecular Sciences;2022-12-10